Table 2.
Baseline characteristics of patients with PTCLs according to CNS involvement
| Without CNS involvement (%) | With CNS involvement (%) | |
| Number of cases (total N = 228) | 208 | 20 |
| Sex | ||
| Male | 133 (63.9) | 10 (50.0) |
| Female | 75 (36.1) | 10 (50.0) |
| Age (years) | ||
| ≤50 | 92 (44.2) | 9 (45.0) |
| >50 | 116 (55.8) | 11 (55.0) |
| ECOG PS | ||
| PS 0–1 | 148 (71.2) | 11 (55.0) |
| PS 2–4 | 60 (28.8) | 9 (45.0) |
| B symptom | ||
| Present | 93 (45.1) | 7 (35.0) |
| Absent | 113 (54.9) | 13 (65.0) |
| Serum LDH | ||
| ≤Upper normal limit | 82 (39.6) | 2 (10.0) |
| >Upper normal limit | 125 (60.4) | 18 (90.0) |
| Number of extranodal site involvement | ||
| 0–1 | 131 (63.3) | 10 (50.0) |
| 2 or more | 76 (36.7) | 10 (50.0) |
| Visceral organ involvement | ||
| Present | 71 (34.1) | 11 (55.0) |
| Absent | 137 (65.9) | 9 (45.0) |
| Bone marrow involvement | ||
| Present | 81 (39.1) | 6 (30.0) |
| Absent | 126 (60.9) | 14 (70.0) |
| Sinonasal area involvement | ||
| Present | 25 (12.0) | 6 (30.0) |
| Absent | 183 (88.0) | 14 (70.0) |
| Ann Arbour stage | ||
| I/II | 46 (22.1) | 3 (15.0) |
| III/IV | 162 (77.9) | 17 (85.0) |
| International prognostic index risk | ||
| Low/low intermediate | 115 (55.3) | 13 (65.0) |
| High/high intermediate | 93 (44.7) | 7 (35.0) |
| PIT group | ||
| 1/2 | 99 (47.6) | 13 (65.0) |
| 3/4 | 109 (52.4) | 7 (35.0) |
| Histologic subtype | ||
| PTCL-unspecified | 119 | 11 (8.5)a |
| ALCL | 27 | 5 (15.6)a |
| AITL | 49 | 3 (5.8)a |
| EATL | 7 | 1 (12.5)a |
| HSTL | 6 | 0 (0.0)a |
a
Among the same histologic subtype.
PTCL, peripheral T-cell lymphoma; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; PIT, prognostic index for PTCL-NOS; ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; EATL, enteropathy-associated T-cell lymphoma; HSTL, hepatosplenic T-cell lymphoma.